Study of Olverembatinib (HQP1351) in Patients With CP-CML
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
285estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-05 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Myeloid Leukemia
- CML
- CML, Chronic Phase
Interventions
- Drug: olverembatinib
- Drug: Bosutinib
Primary outcomes
what the primary-completion date above is the date OFMMR rate Part A
measured 24 weeks
MMR rate Part B
measured 24 weeks
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed